CURRICULUM VITAE

Evangelos Kolettas, B.Sc. (HONS)$_{(LON)}$, Ph.D.$_{(LON)}$

Professor of Molecular Cell Biology

***Head of the Department of Biology*, School of Medicine, University of Ioannina (UoI), Greece**

***Director, Institute of Biosciences* (IBS), *Centre for Research and Innovation* (CRI), UoI**

***Group Leader/PI, Biomedical Research Institute* (BRI), *Foundation for Research & Technology* (FORTH), Ioannina, Greece**

Tel: 0030-26510-07565; E-mail: ekoletas@uoi.gr; evangelos_kolettas@bri.forth.gr

SHORT CV

Dr. Evangelos Kolettas, B.Sc.(HONS)$_{(LON)}$, Ph.D.$_{(LON)}$, ***Professor of Molecular Cell Biology***

EDUCATION:

- *B.Sc.* (*Hons*) *in Biochemistry* (2.1), University of London, King's College (KCL), Biochemistry Dept.,
- *Ph.D. in Biochemistry* (*Genetics*), Biochemistry Dept., KCL and Genetics Division, MRC National Institute for Medical Research, London (Supervisors: Robin Holliday, FRS & Robert Rosenberger)

Continuing Education: short online courses leading to *Statement of Accomplishment* in:

1. *Experimental Genome Science*, University of Pennsylvania, USA; 03/02/2013
2. *Introduction to Genetics and Evolution*, Duke University, USA; 09/04/2013
3. *Epigenetic Control of Gene Expression*, University of Melbourne, Australia; 05/09/2013
4. *Introductory Human Physiology*, Duke University, USA; 14/11/2013
5. *Genes & Human Condition*: *From Behaviour to Biotechnology*, Maryland Univ.; 7/1/2014

TRAINING:

Postdoctoral Fellow, *Arthritis and Rheumatism Research Council UK*, Department of Biochemistry, Charing Cross and Westminster Medical School, London, UK

Research*: Chondrocyte growth, immortalisation and differentiation*

Undergraduate Teaching: *Biochemistry of Cancer* to MBBS and BSc Biochemistry students

EXPERIENCE:

- Teaching: *Molecular Cell Biology*, *Genetics/Molecular Genetics and Genomics, Biochemistry*, *Cell Signalling*, *Cancer and Stem Cell Biology*, *Molecular Medicine* (*human disease*).
- Research: *Molecular Cancer Biology and Senescence*: Cell signalling and regulatory networks in DNA damage and inflammation involved in senescence and cancer, focusing on cell signalling, transcriptional, epigenetic and translational control mechanisms, using *in vitro* and *in vivo* novel inducible and conditional cell models and conditional transgenic mouse models with emphasis on IKK/NF-κB signalling, and employing bio-imaging, retroviral / lentiviral vectors, CRISPR/Cas9 and high throughput -omics technologies in conjunction with bioinformatics.
- Publications related to research expertise (*Molecular Cell Senescence and Cancer Biology*):
  1. *RIS1, a Ras-induced senescence marker and tumour-suppressor* [Barradas *et al* (2002) Identification of a candidate tumour suppressor gene specifically activated during *ras*-induced senescence. *Exp Cell Res*]
  2. *DNA damage responses in OIS acting as a tumour barrier* [Bartkova *et al* (2006) Oncogene-induced senescence (OIS) is part of the tumourigenesis barrier imposed by DNA damage checkpoints. *Nature*]
  3. *NFκB delays OIS* [Batsi *et al* (2009) Chronic NF-κB activation delays *Ras*-induced premature senescence of human fibroblasts by suppressing the DNA damage checkpoint response. *Mech Ageing Dev*]
  4. *Bcl2-NFκB axis controls cancer cell apoptosis* [Batsi *et al* (2009) Bcl-2 blocks 2-methoxyestradiol induced leukaemia cell apoptosis by a $p27^{Kip1}$ dependent G_1/S cell cycle arrest in conjunction with NF-κB activation. *Biochem Pharmacol*]
  5. *Cdc6 licenses tumour growth and EMT* [Sideridou *et al* (2011) Cdc6 represses E-cadherin transcription and activates adjacent replication origins. *J Cell Biol*]
  6. *Canonical IKKβ/NF-κB pathway protects normal and tumour cells from H_2O_2-induced DDR-dependent senescence & apoptosis, respectively* [Sfikas *et al* (2012) The canonical NF-κB pathway differentially protects normal and human tumour cells from ROS-induced DNA damage. *Cell Signal*]

7. *Comprehensive review on miRNAs in the multi-step process of carconogenesis* [Markopoulos *et al* (2017) A step-by-step miRNA guide to cancer development and metastasis. *Cell Oncol*]
8. *Identification of miRNAs targeting cell cycle genes during replicative senescence with miR-221/222 inducing cell cycle phase arrest* [Markopoulos *et al* (2017) Senescence-associated microRNAs target cell cycle regulation genes in human lung fibroblasts. *Exp Gerontol*]
9. *NF-κB - miRNA network in inflammation and cancer* [Markopoulos *et al* (2018) Roles of NF-κB signalling in the regulation of miRNAs impacting on inflammation in cancer. *Biomedicines*]
10. *IKKα functions as lung tumour suppressor in mice and humans* [Chavdoula *et al* (2019) CHUK/IKKα loss in lung epithelial cells enhances NSCLC growth associated with HIF upregulation. *Life Sci Alliance*]
11. *IKKβ and p65 act as lung tumour promoters* [Roupakia *et al* (2021) Canonical NFκB promotes lung cell tumour growth by downregulating the metastasis suppressor CD82 and enhancing epithelial-to-mesenchymal cell transition. *Cancers*]
12. *RelA/p65 and E2F1 cistromes have limited overlap and bind active chromatin even prior to immunogenic stimulation* [Foutadakis *et al* (2022) An expanded interplay network between NF-κB p65 (RelA) and E2F1 transcription factors: Roles in cell physiology and pathology. *Cancers*]
13. *IKKα in RNA splicing and translation in cancer* [Besta S *et al* (2024) Exploring the interactome of IKKα and its role in alternative RNA splicing in lung cancer. *Poster* / *Oral Presentation*, 14th FORTH Retreat, International Olympic Academy, Ancient Olympia, Greece, 11-13/10/2024. *Presentation Award* (1 of 3)

EMPLOYMENT and POSITIONS:

01/2023: ***Professor of Molecular Cell Biology***, and ***Head of the Department of Biology*** (2024) Department of Biology, School of Medicine, University of Ioannina (UoI), Greece

09/2024: ***Director***, **Institute of Biosciences, Centre for Research and Innovation (CRI), UoI**

09/2025: ***Chair, Division of Functional & Clinical Sciences,* UoI Medical School** (from 01/09)

09/2025: ***Member of the Board of Directors* of the UoI Medial School** (from 01/09)

04/2007: ***Group Leader/PI***, **Biomedical Research Institute (BRI), Foundation for Research and Technology (FORTH)**, Ioannina, Greece

Undergraduate Teaching (MBBS & MSci in Biological Applications & Technology, UoI, MSci BAT):
- *Core Biology I* and *II*: Cell and Molecular Biology/Genetics lectures (MBBS Biology I module lead)
- *Pathological Oncology* (optional course module): Molecular Basis of Cancer (MBBS)
- *Cell Communication & Signalling* (option): NF-κB signalling in inflammation & cancer (MSci BAT)

Postgraduate Teaching:
MSc in Molecular Cell Biology and Biotechnology (2005 - -present)
- *Molecular Cell Biology* (2005 – 2025)
- *Molecular Oncology* (2005 – 2024)

Molecular Cancer Biology and Senescence Research Group

The first research direction is on '*Cell signalling and regulatory networks in DNA damage and inflammation impacting on ageing/senescence and cancer*', with a focus on the role of IKK/NF-κB transcription factors (TFs), that are pivotal regulators of immune, pro-inflammatory and stress responses in health and disease (e.g., inflammatory diseases, cancer). IKK/NF-κB TFs are activated mainly by two signalling pathways: a canonical (IKKβ-RelA(p65)/p50) and a noncanonical (IKKα-RelB/p52) signalling pathway, in response to both extracellular and intracellular stimuli. In addition, the upstream NF-κB activating Ser/Thr kinases IKKα and IKKβ are also involved in the regulation of fundamental cellular processes, with diverse physiological effects in different cells, independently of the activation of the NF-κB TFs (Chavdoula *et al*. 2019 *Life Sci Alliance*; Roupakia *et al* 2021 *Cancers*; Foutadakis *et al*. 2022 *Cancers*).

MicroRNAs act as oncomirs or tumour suppressors involved in cancer and senescence (Markopoulos *et al* 2017 *Cell Oncol*; Markopoulos *et al* 2017 *Exp Gerontol;* Foutadakis *et al* 2025 *Meth Mol Biol*). Specifically, we identified, by Nanostring miRNA analysis, IKKα-regulated miRNAs acting as oncomir in NSCLC *in vivo* xenografts in NSG mice. RNA-seq analysis revealed an EMT and an interferon-inflammatory signature, including TNF-NFκB signalling in NSCLC cells overexpressing IKKα-regulated miRNA.

We will also study the role of these IKKα-regulated miRNAs and the role of extracellular vesicles miRNAs in senescence of normal and cancer human lung cells.

A second research direction involves *functional domain-specific CRISPR/Cas9 screens such as kinase, TFs and epigenetic regulators to identify novel regulators of cell growth and behaviour*, including novel regulators of DNA damage and inflammation involved in senescence and cancer.

6/2015 - 01/2023: ***Asc. Prof. of Molecular Cell Biology***, Biology Dept., School of Medicine, UoI

Undergraduate and Postgraduate teaching, and Research: As above

2014 - 6/2015: ***Associate Professor of Physiology with emphasis in Molecular Physiology***
Department of Biology, School of Medicine, FHS, UoI, Greece

Undergraduate and Postgraduate teaching, and Research: As above

2002 - 2014: ***Assistant Professor of Physiology with emphasis in Molecular Physiology***
Department of Physiology, School of Medicine, UoI, Greece

Undergraduate Teaching in *Human Physiology*, MBBS (2003-2014):

- *Cell Physiology*, including *Biological Membrane Structure-Function and Transport*
- *Digestive System Physiology*

Postgraduate Teaching:

1. MSc in Agricultural Product Assurance and Quality (2003-2008):
   (a) *Genetically-modified organisms*, and (b) *Environmental pollution and mutagenesis*
2. MSc in Pain Control (2004-2013): *Physiology of the Digestive system*
3. MSc in Agro-chemistry and Biological Products (2004-13): *Animal Biotechnology*
4. MSc in Biotechnology (2008-14): *Molecular Biology of the Gene* (module): *Cell cycle regulation*

Cancer Biology and Senescence Research Group: *IKK/NF-κB signalling in senescence and cancer*

1995 - 1998: ***Lecturer in Biochemistry*** (Fixed-term)
Department of Biochemistry, School of Medicine, University of Thessaly, Larisa, Greece

Undergraduate Teaching:

- *Biochemistry I*: Topics in general and metabolic biochemistry
- *Biochemistry II*: Biochemistry of connective tissues and extracellular matrix

6/2 - 26/2/97: ***Visiting Research Scientist*** (Travel grant), Wellcome Trust Centre for Cell-Matrix Research & Biochemistry Division, School of Biological Sciences, University of Manchester

Research: *Modulation of chondrocyte differentiation by cytokines*

ADMINISTRATION DUTIES: *Head of the Department of Biology*, *Chairman of the Division Functional & Clinical Sciences* (01/09/2025), *Member of the Board of Directors* (01/09/2025) and the *General Assembly* of the UoI Medical School, Director of the UoI Institute of Biosciences; Member of the Scientific Council of BRI, FORTH (2022-2024); Internal and external assessor for academic staff selection/promotion in Greece and UK; MSc committee member; Course module development and lead; Research group leader, managing teams, consortia and budgets; Research infrastructure and planning committees; Project/Thesis supervision and examination committees; MoUs between UoI, Cyprus (2007-2024) and Brunel (2023-26) and Monash (2025-27) Universities. UoI and Monash are developing a joint *MSc in Medical Genetics & Genomics*; Editorial work; Journal & Grant reviewer in Greece, UK and internationally; Organisation of seminars, national and international conferences.

PROJECT / THESIS SUPERVISION

- Higher Diploma Projects: 4
- BSc Projects: 6
- MSci Projects: 2
- MSc theses: 10 (3 as co-supervisor)
- MSc theses examination committees: 9
- PhD theses, as: (a) *Main supervisor*: 8 (completed) (b) *Co-supervisor*: 13 (9 completed)
  (c) PhD theses examination committees: 29 (incl. Nottingham Trent, Brunel, Sussex Universities)
- Internal and external undergraduate and postgraduate project / theses examiner
- Postdoctoral Supervision: 4
- Mentoring ECRs (Postdocs, Lecturers, Ast. Professors): 14

SUMMARY OF PUBLICATIONS

- *Methods book series*: Two chapters in '*Cell and Tissue Culture*: *Laboratory Procedures*' (Wiley & Sons, Publ.), on gene transfer methods of oncogenes in mammalian cells (1994)
- *Books* / *Chapters*: Scientific co-editing / translation in Greek of Textbooks and/or Chapters (Ch):
  - '*Human Physiology*: *From Cells to Systems*', L. Sherwood (2012) 8th edn, Cengage, Co-editor and translation/editing of Chapter 16: Digestive System (Academic Press, Greece, 2014)
  - '*Molecular Cell Biology*', Lodish *et al* (2016), 8th edn, Freeman & Co; Co-editor and translation of Chapter 5: Fundamental Molecular Genetic Mechanisms (Utopia, Greece, May 2020)
  - '*Principles of Development*', Wolpert *et al* (2019), 6th e, OUP, Ch1: *History and Basic Concepts*
- **58** abstracts/posters to national, British, European and international conferences/workshops.
- **55** publications in peer-reviewed journals [*Nature, J Cell Biol, Cell Res (Springer Nat), J Exp Clin Cancer Res (BMC Nat), J Cell Sci, Life Sci Alliance, Cell Oncol, Cancers, Biochem Pharmacol, Free Rad Biol Med, J Cell Mol Med, Cell Signal, Rheumatol, Biomedicines, Cells, Eur J Biochem, FEBS J, FEBS Lett, Exp Cell Res, Exp Gerontol, Mech Ageing Dev, J Cell Biochem, J Mol Biol, Mobile DNA, J Theor Biol, Arch Biochem Biophys, Mol Cell Biochem, Int J Oncol, ACS Chem Biol, Sensors & Actuators: B. Chem, Meth Mol Biol, etc*].

One manuscript has been submitted, and another one is under preparation. My work with IF~335 has received in Google Scholar 4560 citations, *h*25; Scopus 3215, *h*21; ResearchGate 4120, *h*24.

EDITORIAL WORK

- Associate Editor of *CANCER GENE THERAPY* (Springer Nature, 2024-2026)
- Editorial board member of *CANCERS* (Section: '*Molecular Cancer Biology*' (2023-25)
- Editorial board member of *BIOMEDICINES* (Section: '*Cancer Biology and Oncology*' (2022-26)
- Guest co-editor for a special issue of *CELLS* (2021-22), on: '*The DNA Damage Response in Cell Physiology and Disease*'
- Guest co-editor for a special issue of *CANCERS* (2021-22), on: '*NF-κB signalling in cellular responses to threats, cancer development and therapy*

RESEARCH GRANTS (25 competitive grants as PI, co-PI, consortium coordinator, member)

- 1997 - 2009: 14 grants (10 as PI and 2 as co-PI), 395.000 €
- 2012 - 2020: 8 grants (1 as Coordinator, 5 as PI and 2 as Member), 2.495.000 €
- 2020 - 2024: 1 grant (1 University Consortium BIOMED-20 grant, 3 m €
- 2024 - 2026: 1 Internal bridging grant, 10.000 €
- 2025 - 2027: 1 'Th. Papazoglou' FORTH Synergy Grant, 80.000 € (PI: M. Georgiadou; collaborator)

GRANT / JOURNAL REVIEWER

- 53 grant proposals submitted to national (34), European (15) and International (4) funding bodies: UKRI-BBSRC, Academy of Medical Sciences-UK, Breast Cancer Now-UK, Leverhulme Trust-UK, CCLG: The Children & Young People's Cancer Association-UK, WCR, MRC South Africa, Czech Science Foundation. Panel member of the Hellenic Foundation for Research & Innovation (HFRI).
- 83 papers (*Biochem J, Biochem Pharmacol, Biol Cell, Biomedicines, BMC Cancer, Cancer Gene Ther, Cancers, BJC, JECCR, Cell Cycle, Cell Death Dis, Commun Biol, Exp Gerontol, FEBS J, J Cell Mol Med, J Cell Physiol, JCI, J Hepatol, iSci, Mech Ageing Dev, Oncogene, Open Biol, Sci Rep, Stem Cells Transl Med*)
- Book Review: '*MicroRNA in human malignancies*', Negrini M, Calin G, Croce C; Elsevier, 2022

MEMBERSHIP: Hellenic Society of Biochemistry & Molecular Biology, Hellenic Society of Biological Sciences, Hellenic Association for Molecular Cancer Research, Cancer Epigenetics Society.

CONFERENCE / WORKSHOP ORGANISATION (Member of the organising/scientific committee)

- 3rd European NF-κB subunit workshop, Corfu, Greece (10/2016).
- 67th Hellenic Society of Biochemistry & Molecular Biology conference, Ioannina, Greece (11/2016)

CONFERENCES (Attended National, British, European and International Conferences): **44**

SCIENTIFIC LECTURES (Invited; National, Cyprus, UK including Essex, Sussex and Brunel U): **35**

PUBLICATIONS

I. *Textbooks and Textbook Chapters*

1. ***Human Physiology: From Cells to Systems*** by **Lauralee Sherwood, 8th International edition 2012, Brooks/Cole Cengage Learning**; Chapters 20, pp928.
   Scientific Co-editing of the translation in Greek of the textbook; *Co-editors*: **E. Kolettas**, and A. Psarropoulou, Department of Biological Applications and Technology, University of Ioannina; and Scientific editing/translation of Chapter 16: The Digestive System.
   Publishers: Academic Press, Greece (2014).

2. ***Molecular Cell Biology***, by **Lodish H, Berk A, Kaiser CA, Krieger M, Bretscher A, Ploegh H, Amon A and Martin KC, 2016, 8th edition, WH Freeman & Co**, 24 Chapters, pp1166.
   Scientific Co-editing of the translation in Greek of the textbook (Eds: **Kolettas E**, Marangos P and Georgatos SD), and Translation/editing of Chapter 5: *Fundamental Molecular Genetic Mechanisms* (Part II: Biomembranes, Genes and Gene Regulation), 2020; *Publishers*: Utopia Publishing Co., Greece (April 2020).

3. ***Principles of Development***, by **Wolpert L, Tickle C and Arias AM**, **2019, 6th edition; Oxford University Press**. (Editor: P. Marangos). Scientific translation of Chapter 1: *History and Basic Concepts of Development*. *Publishers*: Broken Hill Publ. Ltd, Cyprus (May 2020)

II. *Chapters in Book Series* (**2**)

1. **Kolettas E**, Gonos ES and Spandidos DA. (1994). Retroviral genes - *Myc*. Chapter 26: Immortalisation Methods, Units 26.7.1, Part 26H, Module 26H:1. In ***Cell and Tissue Culture*: *Laboratory Procedures*** (Griffiths JB, Doyle A and Newell DG, Eds), John Wiley & Sons, Ltd.
2. Gonos ES, **Kolettas E** and Spandidos DA. (1994). Retroviral genes - *Ras*. Chapter 26: Immortalisation Methods, Units 26.7.2, Part 26H, Module 26H:2. In ***Cell and Tissue Culture*: *Laboratory Procedures*** (Griffiths JB, Doyle A and Newell DG, Eds), John Wiley & Sons, Ltd.

III. *Conferences - Oral Presentations & Posters*: 43

IV. *Selected Abstracts Published in Journals*: 13 (*Matrix Biol*, *Cancer Res*, *FEBS J*, Blood)

V. *Journal Publications* (**Total: 55**)

1. Rosenberger RF, Gounaris EG and **Kolettas E**. (1991). Mechanisms responsible for the limited and immortal phenotype in cultured mammalian cells. ***J. Theor. Biol***. 148:383-392.
2. **Kolettas E***, Gonos ES and Spandidos DA. (1994). Overexpression of *Ha-Ras* oncogene transforms rodent fibroblasts with low frequency but not human diploid fibroblasts. ***Int. J. Oncol***. 4:43-47.
3. **Kolettas E**, Buluwela L, Bayliss MT and Muir HI. (1995). Expression of cartilage-specific molecules remains unaffected by long-term culture of human articular chondrocytes. ***J. Cell Sci***. 108:1991-1999.
4. **Kolettas E***, Spandidos DA and Rosenberger RF. (1997). SV40 transformation of embryonic human diploid fibroblasts results in multiple changes in gene expression. ***Int. J. Oncol***. 11(4):717-725.
5. **Kolettas E***, Khazaie K and Rosenberger RF. (1997). Overexpression of the human *c-erbB* (*EGF Receptor*) proto-oncogene fails to alter the lifespan or promote tumourigenic growth of normal and SV40-transformed human fibroblasts. ***Int. J. Oncol***. 11(5):1071-1080.
6. Yu RCH, **Kolettas E**, Kamalati T, Chu AC and Buluwela L. (1997). Stable expression of CD1a molecule in human epithelial cell lines shows temperature-dependent expression and affects cell morphology and growth. ***Arch. Dermatol. Res***. 289(6):352-359.
7. **Kolettas E***, Lymboura M, Khazaie K and Luqmani YA. (1998). Modulation of human elongation factor 1-delta gene expression by oncogenes in human epithelial cells. ***Anticancer Res***. 18:385-392.

8. **Kolettas E** and Rosenberger RF. (1998). Suppression of decorin gene expression and induction of anchorage-independent growth by overexpression of *v-src* oncogene in human fibroblasts. ***Eur. J. Biochem***. 254(2):266-274.
9. Assimakopoulos DA, **Kolettas E**, Zagorianakou N, Evangelou A, Skevas A and Agnantis N. (2000). Prognostic significance of p53 in the cancer of the larynx. ***Anticancer Res***. 20(5):3555-3564 (Invited Review).
10. Paschos I, Natsis L, Nathanailidis C, Kagalou I and **Kolettas E**. (2001). Induction of androgenesis and gynogenesis in the goldfish *Carassius auratus* oranda. ***Reprod. Dom. Animals*** 36:195-198.
11. **Kolettas E***, Muir HI, Barrett JC and Hardingham TE. (2001). Chondrocyte phenotype and cell survival are regulated by culture conditions and by specific cytokines through the expression of *Sox9* transcription factor. ***Rheumatology*** 40(10):1146-1156.
12. **Kolettas E***, Evangelou E and Gonos ES. (2001). *v-FBR-fos* oncogene fails to rescue mammalian cells from growth arrest but affects the responses of human fibroblasts to heparin. ***Anticancer Res***. 21(1A):435-444.
13. Petropoulou C, Trougakos I, **Kolettas E**, Toussaint O and Gonos ES. (2001). Clusterin / Apolipoprotein J is a novel biomarker of cellular senescence that does not affect the proliferative capacity of human diploid fibroblasts. ***FEBS Lett***. 509:287-297.
14. Barradas M, Gonos ES, Zebedee Z, **Kolettas E**, Petropoulou C, Delgado MD, Leon J, Hara E and Serrano M. (2002). Identification of a candidate tumour suppressor gene specifically activated during *ras*-induced senescence. ***Exp. Cell Res***. 173(2):127-137.
15. Gonos ES, Agrafiotis D, Dontas AS, Efthimiopoulos S, Galaris D, Karamanos NK, Kletsas D, **Kolettas E**, Panagyotou G, Sekeri-Pataryas KE, Simoes D, Sourlingas TG, Stathakos D, Stratigos AJ, Tavernarakis N, Trougakos IP, Tsiganos CP and Vinyos DH. (2002). Ageing Research in Greece. ***Exp. Gerontol***. 37(6):735-747.
16. Assimakopoulos DA, **Kolettas E**, Evangelou A and Patrikakos G. (2002). The role of CD44 in the development and prognosis of squamous cell carcinoma of head and neck. ***Histol. Histopathol***. 17(4):1269-1281. (Invited Review).
17. Charalabopoulos K, Papalimneou V, Evangelou A, Kalfakakou V, Kiortsis D, **Kolettas E**, Alamanos J, Charalabopoulos A and Agnantis NJ. (2003). Is the E-cadherin downregulation observed in Helicobacter pylori infection associated with gastric cancer development? An additional element in the disease jigsaw. ***Exp. Oncol***. 25(4):270-273.
18. Kontargiris E, **Kolettas E**, Vadalouca A, Trougakos IP, Gonos ES and Kalfakakou V. (2004). Ectopic expression of clusterin/apolipoprotein J or Bcl-2 decreases the sensitivity of HaCaT cells to toxic effects of ropivacaine. ***Cell Res***. 14(5):415-422. (*NPG Journals*)
19. Bartkova J, Rezai N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, **Kolettas E**, Niforou K, Zoumpourlis VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L, Ørntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD, Bartek J and Gorgoulis VG. (2006). Oncogene-induced senescence is part of the tumourigenesis barrier imposed by DNA damage checkpoints. ***Nature*** 444(7119):633-637.
20. **Kolettas E***, Skoufos I, Kontargiris E, Markopoulou S, Tzavaras T and Gonos ES. (2006). Bcl-2 but not clusterin/apolipoprotein J protected human diploid fibroblasts and immortalised keratinocytes from ceramide-induced apoptosis: Role of p53 in the ceramide response. ***Arch. Biochem. Biophys***. 445:184-195.
21. **Kolettas E***, Thomas C, Leneti E, Skoufos I, Mbatsi C, Sisoula C, Manos M and Evangelou A. (2006). Rosmarinic acid failed to suppress hydrogen peroxide-mediated apoptosis but induced apoptosis of Jurkat cells which was suppressed by Bcl2. ***Mol. Cell. Biochem***. 285:111-120.
22. Barbouti AK, Amorgianiotis CG, **Kolettas EM**, Kanavaros PE and Galaris DA. (2007). Hydrogen peroxide inhibits caspase-dependent apoptosis by inactivating procaspase-9 in an iron-dependent manner. ***Free Rad. Biol. Med***. 43:1377-1387.
23. Noutsopoulos D, Markopoulos G, Koliou M, Dova L, Vartholomatos G, **Kolettas E** and Tzavaras T. (2007). Vanadium induces VL30 retrotransposition at an unusually high level: A possible carcinogenesis mechanism. ***J. Mol. Biol***. 374:80-90.
24. Markopoulou S, Kontargiris E, Batsi C, Tzavaras T, Trougakos IP, Boothman DA, Gonos ES and **Kolettas E*.** (2009). Vanadium-induced apoptosis of HaCaT cells is mediated by *c-fos* and involves nuclear accumulation of clusterin. ***FEBS J***. 276:4208-4223.

25. Batsi C, Markopoulou S, Vartholomatos G, Georgiou I, Kanavaros P, Gorgoulis VG, Marcu KB and **Kolettas E***. (2009). Chronic NF-κB activation delays *Ras*^{V12}-induced premature senescence of human fibroblasts by suppressing the DNA damage checkpoint response. ***Mech. Ageing Dev***. 13:409-419.

26. Batsi C, Markopoulou S, Kontargiris E, Charalambous Ch, Thomas Ch, Christoforidis S, Kanavaros P, Constantinou AI, Marcu KB and **Kolettas E***. (2009). Bcl-2 blocks 2-methoxyestradiol induced leukaemia cell apoptosis by a p27^{Kip1} dependent G_1/S cell cycle arrest in conjunction with NF-κB activation. ***Biochem. Pharmacol***. 78:33-44.

27. Noutsopoulos D, Markopoulos G, Vartholomatos G, **Kolettas E**, Kolaitis N and Tzavaras T. (2010). VL30 retrotransposition signals activation of the mitochondrial death pathway in a caspase-independent and p53- and lysosomal damage-dependent manner. ***Cell Res***. 20:553-562. (*NPG Journals*).

28. Sigala F, Savvari P, Liontos M, Sigalas P, Pateras IS, Papalampros A, Basdra E, **Kolettas E**, Kotsinas A, Papavassiliou AG and Gorgoulis VG. (2010). Increased expression of bFGF is associated with carotid atheromatic plaques instability engaging the NF-κB pathway. ***J. Cell. Mol. Med***. 14:2273-2280.

29. Sideridou M, Zakopoulou R, Evangelou K, Liontos M, Kotsinas A, Rampakakis E, Gagos S, Kahata K, Grabusic K, Gkouskou K, Trougakos IP, **Kolettas E**, Georgakilas G, Volarevic S, Eliopoulos AG, Zannis-Hadjopoulos M, Moustakas A and Gorgoulis VG. (2011). Cdc6 expression represses E-cadherin transcription and activates adjacent replication origins. ***J. Cell Biol***. 195:1123-1140 [*In Focus*: Leslie M (2011) Cdc6 licenses tumour growth. *JCB* 195:106]

30. Konisti S, Mantziou S, Markopoulos G, Thrasyvoulou S, Vartholomatos G, Sainis I, **Kolettas E**, Noutsopoulos D and Tzavaras T. (2012). H_2O_2 signals via iron induction of VL30 retrotransposition correlated with cytotoxicity. ***Free Rad. Biol. Med***. 52:2072-2081.

31. Sfikas A, Batsi C, Tselikou E, Monokrousos N, Pappas P, Vartholomatos G, Christoforidis C, Tzavaras T, Kanavaros P, Gorgoulis VG, Marcu KB and **Kolettas E***. (2012). The canonical NF-κB pathway differentially protects normal and human tumour cells from ROS-induced DNA damage. ***Cellular Signalling*** 24:2007-2023.

32. Primikyri A, Chatziathanasiadou M, Karali E, Kostaras E, Mantzaris M, Hatzimichael E, Shin JS, Chi S-W, Briasoulis E, **Kolettas E**, Gerothanassis IP and Tzakos AG. (2014). Direct binding of Bcl-2 family proteins by quercetin triggers its pro-apoptotic activity. ***ACS Chem. Biol***. 9:2737-41

33. Karapetsas A, Tokamani M, **Kolettas E** and Sandaltzopoulos R. (2015). Novel microRNAs as putative therapeutic targets in cardiovascular diseases. ***Curr Vascular Pharmacol***. 13(5):564-5 (*Editorial*).

34. Markopoulos G, Noutsopoulos D, Mantziou S, Gerogiannis D, Thrasyvoulou S, Vartholomatos G, **Kolettas E** and Tzavaras T. (2016). Genomic analysis of mouse VL30 retrotransposons. ***Mobile DNA*** 7:10, May 6(10.1186/s13100-016-0066-8)

35. Markopoulos G, Roupakia E, Tokamani M, Chavdoula E, Hatziapostolou M, Polytarchou C Marcu KB, Papavassiliou AG, Sandaltzopoulos R and **Kolettas E***. (2017). A step-by-step microRNA guide to cancer development and metastasis. ***Cell Oncol***. 40(4):303-339.

36. Markopoulos G, Roupakia E, Tokamani M, Vartholomatos G, Tzavaras T, Hatziapostolou M, Fackelmayer FO, Sandaltzopoulos R, Polytarchou C and **Kolettas E***. (2017). Senescence-associated microRNAs target cell cycle regulation genes in human lung fibroblasts. ***Exp. Gerontol***. 96:110-122.

37. Ypsilantis K, Plakatouras JC, Manos MJ, Kourtellaris A, Markopoulos G, **Kolettas E** and Garoufis A. (2018). Stepwise synthesis, characterization, DNA binding properties and cytotoxicity of diruthenium oligopyridine compounds conjugated with peptides. ***Dalton Trans*** 47(10):3549-3567

38. Patounas O, Papacharalampous I, Eckerich C, Markopoulos G, **Kolettas E** and Fackelmayer FO (2018). A novel splicing isoform of protein arginine methyltransferase 1 (PRMT1) that lacks the dimerization arm and correlates with cellular malignancy. ***J Cell Biochem***. 119:2110-2123.

39. Markopoulos G, Roupakia E, Tokamani M, Alabasi G, Sandaltzopoulos R, Marcu KB and **Kolettas E***. (2018). Roles of NF-κB signalling in the regulation of miRNAs impacting on inflammation in cancer. ***Biomedicines*** 6(2):40, 198-216.

40. Roupakia E, Markopoulos G and **Kolettas E***. (2018). IL-12-mediated transcriptional regulation of matrix metalloproteinases. ***Bioscience Rep***. 38(3) BSR20171420(*Commentary*)

41. Sundar D, Yu Y, Katiyar SP, Putri J, Dhanjal JK, Wang J, Sari AN, **Kolettas E**, Kaul SC and Wadhwa R. (2019). Wild type p53 function in $p53^{Y220C}$ mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: Bioinformatics and experimental evidence. ***J. Exp. Clin. Cancer Res***. 38(1):103 (1-14) (*BMC-Springer Nature*)

42. Markopoulos G, Roupakia E, Marcu KB and **Kolettas E***. (2019). Epigenetic regulation of inflammatory cytokine-induced epithelial-to-mesenchymal cell transition and in the generation of cancer stem cells. ***Cells*** 8(10), Sep 25, pii: E1143.

43. Chavdoula E, Habiel DM, Roupakia E, Markopoulos GS, Vasilaki E, Kokkalis A, Polyzos A, Boleti H, Thanos D, Klinakis A, **Kolettas E*** and Marcu KB*. (2019). CHUK/IKKα loss in lung epithelial cells enhances non-small cell lung cancer (NSCLC) growth associated with HIF up-regulation. ***Life Science Alliance*** 2(6):e201900460 (10.26508/lsa.201900460).

44. Ntellas P, Mavroeidis L, Gkoura S, Gazouli I, Amylidou A-L, Papadaki A, Zarkavelis G, Mauri D, Karpathiou G, **Kolettas E**, Batistatou A and Pentheroudakis G. (2020). Old player-new tricks: Non angiogenic effects of the VEGF/VEGFR pathway in cancer. ***Cancers*** 12(11):E3145.

45. Tsiailanis A, Renziehausen A, Kiriakidi S, Vrettos EI, Markopoulos GS, Sayyad N, Hirmiz B, Aguilar M-I, Del Borgo MP, **Kolettas E**, Widdop RE, Mavromoustakos T, Crook T, Syed N and Tzakos AG. (2020). Enhancement of glioblastoma multiforme therapy through a novel Quercetin-Losartan hybrid. ***Free Rad. Biol. Med***. 160:391-402.

46. Roupakia E, Markopoulos GS and **Kolettas E***. (2021). Genes and pathways involved in senescence bypass identified by functional genetic screens. ***Mech. Ageing Dev***. 194:111432.

47. Basagiannis D, Zografou S, Goula E, Gkeka D, **Kolettas E** and Christoforidis S. (2021). Chemical inhibitors of dynamin exert differential effects in VEGF signalling. ***Cells*** 10(5):997.

48. Diamantis DA, Agalou A, Chatziathanasiadou MV, Markopoulos GS, Bellou S, Kanaki Z, Crook T, Syed N, Rampias T, Klinakis A, **Kolettas E**, Beis D and Tzakos AG. (2021). Biotin-Yellow, a biotin guided NIR turn-on fluorescent probe for cancer targeted diagnosis. ***Sensors and Actuators: B. Chemical*** 337:129807.

49. Roupakia E, Chavdoula E, Karpathiou G, Vatsellas G, Hatzopoulos D, Kriegsmann K, Kriegsmann M, Mela A, Gillette JM, Batistatou A, Goussia A, Marcu KB, Karteris E, Klinakis A and **Kolettas E***. (2021). Canonical NF-κB promotes lung epithelial cell tumour growth by downregulating the metastasis suppressor CD82 and enhancing epithelial-to-mesenchymal cell transition. ***Cancers*** 13(17):4302.

50. Foutadakis S, Roupakia E, Liakopoulos P, Kolovos P* and **Kolettas E***. (2022). An expanded interplay network between NF-κB p65 (RelA) and E2F1 transcription factors: Roles in physiology and pathology. ***Cancers*** 14(20):5047.

51. Ntinopolou M, Cassimos D, Roupakia E, **Kolettas E**, Panopoulou M, Mantadakis E, Konstantinidis Th and Chrysanthopoulou A. (2023). IL-17A-enriched Neutrophil Extracellular Traps promote immunofibrotic aspects of childhood asthma lung attack. ***Biomedicines*** 11(8):2104.

52. Sifnaiou E, Tsolis Th, Ypsilantis K, Roupakia E, **Kolettas E**, Plakatouras JC and A Garoufis A. (2024). Synthesis and characterization of ruthenium-paraphenylene-cyclopentadienyl full-sandwich complexes: cytotoxic activity against A549 lung cancer cell line and DNA binding properties. ***Molecules*** 29(1):17 (2775878).

53. Koumpis E, Papoudou-Bai A, Papathanasiou K, **Kolettas E**, Kanavaros P and Hatzimichael E. (2024). Unraveling the immune microenvironment in diffuse large B-cell lymphoma: Prognostic and therapeutic implications. ***Curr. Iss. Mol. Biol***. 46(7):7048-7064.

54. Koumpis E, Georgoulis V, Papathanasiou K, Papoudou-Bai A, Kanavaros P, **Kolettas E** and Hatzimichael E. (2024) The role of microRNA-155 as a biomarker in diffuse large B-cell lymphoma. ***Biomedicines*** 12:2658.

55. Foutadakis S, Soureas K, Roupakia E, Besta S, Avgeris M* and **Kolettas E***. (2025). Identification of oncogene-induced senescence-associated microRNAs. ***Meth Mol Biol*** 2906:189-2013. In: Gorgoulis VG, Cavinato M and Evangelou K (eds) Oncogene-Induced Senescence. Methods in Molecular Biology, Humana, New York, NY.

(*****correspondence)